Clinical Laserthermia Systems AB (publ) announced that for the first-time clinical data has been presented from the investigator-initiated study at Radboud University Medical Center in Nijmegen, the Netherlands, on the use of CLS's MR-guided TRANBERG® system for Focal Laser Ablation (FLA) of localized prostate cancer. During the ECR (European Congress of Radiology) annual meeting in Vienna, Austria, an abstract by the principal investigator for the ongoing study at Radboud University Medical Center (RUMC), Prof. Jurgen Fütterer and his team was presented "MRI-guided transrectal focal laser ablation for localized low and intermediate risk prostate cancer". The presentation covered initial experiences and data from the first sex patients in the ongoing trial at RUMC.

The aim of the study is to investigate the feasibility and safety of the TRANBERG® MR-guided system using MR thermometry by Thermoguide? for accurate ablation control. By use of this system more precise tissue ablation, without damaging vital adjacent structures, is expected.

As stated in the abstract the initial experiences support this hypothesis as the data indicates good oncological response and potential improvement in urinary and sexual function.